IceCure Medical Announces FDA Advisory Panel Meeting To Review ProSense System For Tumor Cryoablation
$ICCM
Medical/Dental Instruments
Health Care
IceCure Medical Announces FDA Advisory Panel Meeting To Review ProSense System For Tumor Cryoablation
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/2/2022 | $5.65 | Buy | Brookline Capital |
| 9/22/2021 | $14.50 | Buy | Alliance Global Partners |
CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day. Conference call & webcast info: Tuesday, November 26, 2024, at 10:00 am EST US: 1-888-407-2553 Israel/Inte
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists PRECICE is exclusively using ProSense® to treat all 233 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than ICE3 Article published in European Journal of Cancer Prevention describes the PRECICE study and presents the role of cryoablation in the move toward de-escalation of surgical treatment CAESAREA, Israel, Nov. 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medi
FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel, Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel's (the "Advisory Panel") favorable recommendation with 9 panelists voting in favor and 5 voting against the benefit-risk profile of IceCure's ProSense®. The majority of panelists voted that the benefits of IceCure's ProSense® System outweigh the risks when us
Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65
Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50
Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha
Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin
CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie
SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)
SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)
SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)
F-1/A - IceCure Medical Ltd. (0001584371) (Filer)
6-K - IceCure Medical Ltd. (0001584371) (Filer)
F-1/A - IceCure Medical Ltd. (0001584371) (Filer)
CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day. Conference call & webcast info: Tuesday, November 26, 2024, at 10:00 am EST US: 1-888-407-2553 Israel/Inte
Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024. Significant Near and Short Term Value Enhancing Catalysts U.S. Food and Drug Administration ("FDA") Medical Device Advisory Committee expected
CAESAREA, Israel, Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Tuesday, August 20, 2024, at 10:00 am EDTUS: 1-888-407-2553Israel/International: +
IceCure Medical Ltd. (NASDAQ:ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The
Study Shows High Complete Ablation Rate And Satisfactory Overall Survival In Breast Cancer Patients; Conducted At University Hospital Frankfurt By Prof. Thomas J. Vogl, Study Highlights 8.9% Recurrence Rate In 45 Patients With Tumors Up To 4cm, Including High-Risk Population With Recurrent And Metastatic Disease